Augustine Therapeutics

Augustine Therapeutics

Foundation date

2019

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Augustine Therapeutics focuses on the development of new medicines to treat severe debilitating diseases with high unmet need, in particular Charcot-Marie-Tooth disease (CMT) as well as other peripheral neuropathies. Augustine Therapeutics completed a seed financing round of €4.2 million in December 2019 with the support of VIB, V-Bio Ventures and PMV joined by Advent France Biotechnology and the Gemma Frisius Fund. Augustine Therapeutics is a drug discovery company building a portfolio of first-in-class drugs rooted in the ground-breaking research on neurodegenerative disorders of Prof. Ludo Van Den Bosch, Prof. Joris De Wit and Prof. Bart De Strooper at VIB.

Upcoming events

Latest news

  • miDiagnostics to pilot innovative, fast COVID-19 PCR testing solutions at Brussels Airport

    15 hours ago

  • VIB celebrates 25 years of groundbreaking research

    Wednesday October 13th 2021

  • Oxurion NV announces first patient dosed in its Phase 2 Study evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)

    Wednesday October 13th 2021